| Literature DB >> 32474718 |
Gonzalo Luengo-Alonso1, Fernando García-Seisdedos Pérez-Tabernero1, Miguel Tovar-Bazaga1, José Manuel Arguello-Cuenca1, Emilio Calvo2.
Abstract
PURPOSE: SARS-CoV-2's new scenario has forced health systems to work under extreme stress urging to perform a complete reorganization of the way our means and activities were organized. The orthopaedic and trauma units have rescheduled their activities to help SARS-CoV-2 units, but trauma patients require also treatment, and no standardized protocols have been established.Entities:
Keywords: COVID-19; Orthopaedic and trauma; SARS-CoV-2; Surgery; Telemedicine pandemic
Mesh:
Year: 2020 PMID: 32474718 PMCID: PMC7260474 DOI: 10.1007/s00264-020-04647-1
Source DB: PubMed Journal: Int Orthop ISSN: 0341-2695 Impact factor: 3.075
Telematics surveys to patients
Orthopedic surgeon survey
STROBE item used
| Item | Description |
|---|---|
| Title and abstract (1) | (a) Indicate the study’s design with a commonly used term in the title or the abstract |
| (b) Provide in the abstract an informative and balanced summary of what was done and what was found | |
| Introduction | |
| Background/rationale (2) | Explain the scientific background and rationale for the investigation being reported |
| Objectives (3) | State specific objectives, including any prespecified hypotheses |
| Methods | |
| Study design (4) | Present key elements of study design early in the paper |
| Setting (5) | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, and data collection |
| Participant (6) | Give the eligibility criteria, and the sources and methods of selection of participants. |
| Variables (7) | Clearly define all outcomes, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable |
| Data source/measurements (8) | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group. |
| Quantitative variables (11) | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why. |
| Statistical methods (12) | (a) Describe all statistical methods, explain how missing data were addressed if applicable |
| (b) Describe any methods used to examine subgroups and interactions | |
| (c) Explain how missing data were addressed | |
| Result | |
| Participants (13) | Report numbers of individuals at each stage of study—e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed |
| Descriptive data (14) | Indicate number of participants with missing data for each variable of interest |
| Outcome data (15) | Report numbers of outcome events or summary measures over time. |
| Main results (16) | Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision |
| Discussion | |
| Key results (18) | Summarize key results with reference to study objectives |
| Limitations (19) | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias |
| Interpretation (20) | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence |
| Generalisability (21) | Discuss the generalizability (external validity) of the study results |
Group 1: patients pre-SARS-CoV-2 (2019). Group 2: patients SARS-CoV-2 (2020)
| Clinical Evaluation | Surgical procedures | |
|---|---|---|
| Group 1 | 8760 | 304 |
| Group 2 | 6847 | 42 |
| Total | 15,607 | 346 |
Clinical appointments
| Group 1 (pre-SARS-CoV-2) | Group 2 (SARS-CoV-2) | |
|---|---|---|
| Total clinical appointments | 8760 | 7831 |
| Attendance | 7831 (89.39%) | 5134 (74.98%) |
| Urgent appointments | 680 (7.76%) | 334 (4.87%) |
| Non-contact | 929 (10.60%) | 1713 (25.01%) |
| Discharges | 1331 (15.19%) | 837 (12.22%) |
Appointments made in clinic consultation
| Group 1 (pre-SARS-COV-2) | Group 2 (SARS-COV-2) | ||
|---|---|---|---|
| Foot and ankle | Urgent | 5 | 2 |
| Total | 434 | 354 | |
| Knee | Urgent | 18 | 1 |
| Total | 509 | 478 | |
| Hip | Urgent | 5 | 0 |
| Total | 163 | 142 | |
| Spine | Urgent | 45 | 9 |
| Total | 720 | 530 | |
| Hand/microsurgery | Urgent | 29 | 2 |
| Total | 545 | 358 | |
| Shoulder/elbow | Urgent | 12 | 5 |
| Total | 464 | 309 | |
| Total | 2949 | 2190 | |
Surgical procedures comparison
| Group 1 (pre-SARS-COV-2) | Group 2 (SARS-COV-2) | |||
|---|---|---|---|---|
| Outpatients | Inpatients | Outpatients | Inpatients | |
| Elective | 164 | 55 | 0 | 0 |
| Trauma | 7 | 10 | 14 | 2 |
| Hip fractures | 0 | 28 | 0 | 12 |
| Infection | 0 | 11 | 0 | 1 |
| Tumors | 0 | 5 | 0 | 3 |
| Spine | 6 | 18 | 0 | 2 |
| Total | 177 | 127 | 14 | 20 |
Trauma cases attended
| Group 1 (pre-SARS-COV-2) | Group 2 (SARS-COV-2) | |
|---|---|---|
| Hand/microsurgery | 14 | 8 |
| Shoulder and elbow | 19 | 6 |
| Lower extremity | 18 | 10 |
| Hip fractures | 28 | 12 |
| Total | 79 | 36 |
ED trauma cases
| Group 1 (pre-SARS-COV-2) | Group 2 (SARS-COV-2) | |
|---|---|---|
| Less than 48 h | 75 | 23 |
| More than 48 h | 3 | 7 |
| More than 7 days | 1 | 6 |
| Total | 79 | 36 |
Survey results after interviewing 16 orthopedic surgeons
| Satisfaction (0–10) | Clinical evaluations that could be done telematically (0–100%) | |
| Knee | 7.5 | 35% |
| Hip | 8 | 30% |
| Shoulder/elbow | 7 | 25% |
| Spine | 6.5 | 15% |
| Hand/microsurgery | 5 | 22,5% |
| Foot and ankle | 6.5 | 22,5% |
| Trauma | 6.5 | 12,5% |
| Yes | No | |
| 2. Would you prefer a face-to-face evaluation? | 81.25% | 18.75% |
| 3. Do you think a face-to-face consultation would provide more information or change your medical attitude? | 87.5% | 12.5% |
| 4. From now on, do you think a telephone follow-up would be appropriate some of the upcoming evaluations? | 37.5% | 62.5% |
Data obtained from Perceived Quality survey to patients
| Mean | Standard deviation | Range | |
| Age | 58.45 | 16.78 | 18–93 years |
| Telematic evaluation | 8.32 | 1.24 | 3–10 points |
| Information received | 8.01 | 1.57 | 1–10 points |
| Sex | Female (61.9%) | Male (38.1%) | |
| Yes | No | ||
| 3. Did your doctor dedicated enough time during your telematics consultation to evaluate your case? | 91.4% | 8.6% | |
| 4. Are you satisfied with telematics evaluation? | 63.8% | 36.2% | |
| 5. Would you prefer face-to-face evaluation? | 69% | 31% | |
| 6. Do you think that telematics follow-up would be appropriate for some of your upcoming consultations? | 49% | 51% | |
| 7. Would you prefer videoconference instead of phone calls? | 12.4% | 87.6% | |